PT1545710E - Utilização de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil) piridino-3-sulfonamida no tratamento de cancro - Google Patents

Utilização de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil) piridino-3-sulfonamida no tratamento de cancro Download PDF

Info

Publication number
PT1545710E
PT1545710E PT03792501T PT03792501T PT1545710E PT 1545710 E PT1545710 E PT 1545710E PT 03792501 T PT03792501 T PT 03792501T PT 03792501 T PT03792501 T PT 03792501T PT 1545710 E PT1545710 E PT 1545710E
Authority
PT
Portugal
Prior art keywords
methylpyrazin
sulphonamide
oxadiazol
pyridine
methoxy
Prior art date
Application number
PT03792501T
Other languages
English (en)
Inventor
Andrew Mark Hughes
Donna Johnstone
Sian Tomiko Taylor
David William Tonge
Francis Thomas Boyle
Marianne Bernice Ashford
Nigel Charles Barrass
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1545710(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1545710E publication Critical patent/PT1545710E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT03792501T 2002-08-23 2003-08-20 Utilização de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil) piridino-3-sulfonamida no tratamento de cancro PT1545710E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0219660.8A GB0219660D0 (en) 2002-08-23 2002-08-23 Therapeutic use

Publications (1)

Publication Number Publication Date
PT1545710E true PT1545710E (pt) 2009-05-26

Family

ID=9942847

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03792501T PT1545710E (pt) 2002-08-23 2003-08-20 Utilização de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil) piridino-3-sulfonamida no tratamento de cancro

Country Status (31)

Country Link
US (2) US7820679B2 (pt)
EP (2) EP1545710B1 (pt)
JP (2) JP3663202B2 (pt)
KR (1) KR20050035280A (pt)
CN (1) CN100467023C (pt)
AR (1) AR041037A1 (pt)
AT (1) ATE427773T1 (pt)
AU (1) AU2003255835B8 (pt)
BR (1) BR0313655A (pt)
CA (1) CA2496476C (pt)
CL (1) CL2003001692A1 (pt)
CY (1) CY1110712T1 (pt)
DE (1) DE60327084D1 (pt)
DK (1) DK1545710T3 (pt)
ES (1) ES2323309T3 (pt)
GB (1) GB0219660D0 (pt)
IL (1) IL166730A0 (pt)
IS (1) IS2704B (pt)
MX (1) MXPA05001862A (pt)
MY (2) MY136449A (pt)
NO (1) NO330756B1 (pt)
NZ (1) NZ538114A (pt)
PL (1) PL375561A1 (pt)
PT (1) PT1545710E (pt)
RU (1) RU2340343C2 (pt)
SA (1) SA03240363B1 (pt)
SI (1) SI1545710T1 (pt)
TW (1) TWI302912B (pt)
UA (1) UA82071C2 (pt)
WO (1) WO2004018044A2 (pt)
ZA (1) ZA200501267B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
WO2007111350A1 (ja) * 2006-03-28 2007-10-04 Osaka Bioscience Institute 血管新生ならびに癌細胞のmesenchymal型およびamoeboid型浸潤を阻害するための薬剤
US20090062246A1 (en) * 2007-08-17 2009-03-05 Astrazeneca Ab Therapeutic treatment-014
NZ585310A (en) * 2007-10-12 2012-02-24 Astrazeneca Ab Composition 064
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
WO2010004337A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab Combinations comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2- (4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pemetrexed
SG194847A1 (en) * 2011-05-17 2013-12-30 Plexxikon Inc Kinase modulation and indications therefor
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
KR101855382B1 (ko) * 2015-12-31 2018-05-04 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 예방, 치료 및 전이 억제용 약학적 조성물
EP3923939A1 (en) * 2019-02-12 2021-12-22 The University Court Of The University Of Glasgow Microvascular angina

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (pt) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (pt) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
JP3817261B2 (ja) * 1994-04-15 2006-09-06 ファルマシア・アンド・アップジョン・カンパニー １−［５−メタンスルホンアミドインドリル−２−カルボニル］−４−［３−（１−メチルエチルアミノ）−２−ピリジニル］ピペラジンの新規結晶形
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
WO1996009818A1 (en) 1994-09-27 1996-04-04 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
WO1999048530A1 (en) 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
WO2001044239A2 (en) * 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001060370A1 (en) * 2000-02-16 2001-08-23 Yamanouchi Pharmaceutical Co., Ltd. Remedies for endothelin-induced diseases
MXPA02010764A (es) 2000-05-31 2003-03-10 Warner Lambert Co Combinaciones de un antagonista del receptor endotelina y un compuesto antiepileptico que tiene propiedades para aliviar el dolor o analgesico.
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
KR20100036390A (ko) 2001-03-06 2010-04-07 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
EP1379238A1 (en) 2001-04-11 2004-01-14 Abbott Laboratories Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
WO2003015820A1 (en) 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. GnRH AGONIST COMBINATION DRUGS
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
EP1761515B1 (de) 2003-12-20 2008-11-05 MERCK PATENT GmbH 2-(hetero-)aryl substituierte tetrahydrochinolinderivate
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
ES2323309T3 (es) 2009-07-13
CL2003001692A1 (es) 2005-01-21
EP1545710B1 (en) 2009-04-08
JP2005097312A (ja) 2005-04-14
CA2496476C (en) 2009-08-04
IL166730A0 (en) 2006-01-15
TWI302912B (en) 2008-11-11
DK1545710T3 (da) 2009-06-29
EP2072082A3 (en) 2009-12-23
BR0313655A (pt) 2005-06-21
WO2004018044A8 (en) 2004-06-24
NZ538114A (en) 2008-02-29
SI1545710T1 (sl) 2009-08-31
EP2072082A2 (en) 2009-06-24
RU2340343C2 (ru) 2008-12-10
RU2005108349A (ru) 2005-08-27
US20110003831A1 (en) 2011-01-06
US20060094729A1 (en) 2006-05-04
DE60327084D1 (de) 2009-05-20
ZA200501267B (en) 2006-10-25
ATE427773T1 (de) 2009-04-15
UA82071C2 (en) 2008-03-11
NO330756B1 (no) 2011-07-04
EP1545710A2 (en) 2005-06-29
IS7766A (is) 2005-03-22
US7820679B2 (en) 2010-10-26
AR041037A1 (es) 2005-04-27
IS2704B (is) 2010-12-15
MY136449A (en) 2008-10-31
MXPA05001862A (es) 2005-06-03
CY1110712T1 (el) 2015-06-10
SA03240363B1 (ar) 2009-04-11
CN1688365A (zh) 2005-10-26
WO2004018044A2 (en) 2004-03-04
CN100467023C (zh) 2009-03-11
WO2004018044A3 (en) 2004-05-06
MY137595A (en) 2009-02-27
JP3663202B2 (ja) 2005-06-22
AU2003255835A1 (en) 2004-03-11
AU2003255835B8 (en) 2007-05-17
HK1077534A1 (en) 2006-02-17
GB0219660D0 (en) 2002-10-02
KR20050035280A (ko) 2005-04-15
NO20050689L (no) 2005-03-21
TW200409768A (en) 2004-06-16
PL375561A1 (en) 2005-11-28
AU2003255835B2 (en) 2007-04-05
CA2496476A1 (en) 2004-03-04
JP2004083590A (ja) 2004-03-18

Similar Documents

Publication Publication Date Title
PT1663236E (pt) Combinação compreendendo n-(3-metoxi-5-metilpirazin-2-il)-2-(4- [1,3,4-oxadiazol-2-il]fenil)piridina-3-sulfonamida e um bifosfonato
PL378877A1 (pl) Zastosowanie rimeksolonu do leczenia zespołu suchego oka
CY1110712T1 (el) Χρηση ν-(3-μεθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολ-2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδης στη θεραπευτικη αντιμετωπιση του καρκινου
AU2003212634A8 (en) Compounds useful in the treatment of cancer
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
ZA200704104B (en) A combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer
GB0207411D0 (en) Azole compounds and their therapeutic use
FR2840799B1 (fr) Vis d'osteosynthese
EG23929A (en) Isoxazolines derivatives and their use as antidepressants
IS2473B (is) Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess
AU2002352962A8 (en) Novel-n-(4-(1h-imidazol-1-yl)-2-fluorophenyl)-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa
ZA200210316B (en) Composition and its therapeutic use.
PT1532141E (pt) Derivados de 2-pirrolidin-2-il-[1,3,4]-oxadiazole e sua utilização como antidepressivos
IL175303A0 (en) Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
AU2003266965A1 (en) Use of carboxamides for the treatment of tinnitus
IL160310A0 (en) The use of anthroquinones in the treatment of kidney disease
AU2003217432A1 (en) Angiopoietin-1 in the treatment of disease
AU2003247094A8 (en) Enhancing the effect of radioimmunotherapy in the treatment of tumors
IL174968A0 (en) The use of ifenprodil in the treatment of pain
HK1063015A (en) Carbamate compounds for use in the treatment of pain
AU2002357468A1 (en) Use of 2-acylindoles in the treatment of tumors
HK1072713A (en) The treatment of pain with ifenprodil
GB0207412D0 (en) Rhodanine compounds and their therapeutic use
HK1062405A (en) The use of anthroquinones in the treatment of kidney disease
AU2002334251A1 (en) Mifaxin agonists and antagonists for use in the treatment of metabolic